KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Restructuring Costs (2016 - 2025)

Pfizer (PFE) has disclosed Restructuring Costs for 17 consecutive years, with $875.0 million as the latest value for Q4 2025.

  • Quarterly Restructuring Costs fell 41.67% to $875.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, down 43.19% year-over-year, with the annual reading at $1.6 billion for FY2025, 21.99% down from the prior year.
  • Restructuring Costs for Q4 2025 was $875.0 million at Pfizer, up from $237.0 million in the prior quarter.
  • The five-year high for Restructuring Costs was $1.8 billion in Q4 2023, with the low at -$18.0 million in Q2 2025.
  • Average Restructuring Costs over 5 years is $453.0 million, with a median of $206.5 million recorded in 2022.
  • The sharpest move saw Restructuring Costs surged 32050.0% in 2021, then crashed 101.63% in 2025.
  • Over 5 years, Restructuring Costs stood at $643.0 million in 2021, then crashed by 69.05% to $199.0 million in 2022, then soared by 806.03% to $1.8 billion in 2023, then fell by 16.81% to $1.5 billion in 2024, then plummeted by 41.67% to $875.0 million in 2025.
  • According to Business Quant data, Restructuring Costs over the past three periods came in at $875.0 million, $237.0 million, and -$18.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.